All In Biotech

Drug Trial Radar · NCT07201129

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of Cenerimod in Adult Patients With Systemic Lupus Erythematosus and Active Lupus Nephritis in Combination With Background Therapy

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Aug 2029

Study completion Feb 2030

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.

Conditions

  • Nephritis, Lupus
  • Lupus Erythematosus, Systemic

Interventions

  • CenerimodDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

  • PlaceboDrug

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete renal response (CRR)Time frame: At Week 76

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Dolphin Medical Research

    Doral, Florida · Recruiting

  • Alloy Clinical Research LLC

    Kissimmee, Florida · Recruiting

  • SouthCoast Research Center

    Miami, Florida · Recruiting

  • Allied Biomedical Research Institute

    Miami, Florida · Recruiting

  • DH NationalResearchCenters INC

    Miami, Florida · Recruiting

  • ProfessionalResearchCenter INC

    Miami, Florida · Recruiting

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida · Recruiting

  • Revive Research Institute, LLC

    Sterling Heights, Michigan · Recruiting

  • Rheumatology Care Center, PLLC

    Bellaire, Texas · Recruiting

  • Texas Arthritis Center

    El Paso, Texas · Recruiting

  • Novel Research, LLC.

    Houston, Texas · Recruiting

  • Northwest Houston Arthritis

    Houston, Texas · Recruiting

  • Discovery Clinical Trials LLC

    San Antonio, Texas · Recruiting

  • Azul Bioresearch Llc

    Sugarland, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.